← Back to Search

Omega-3 Fatty Acids

Omega-3 Supplements for Cardiovascular Disease (FAS Trial)

N/A
Waitlist Available
Led By Marie-Claude Vohl, Ph.D.
Research Sponsored by Laval University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Healthy men and women aged between 18 to 50 years
Free of any thyroid or metabolic disorders requiring treatment such as diabetes, hypertension, severe dyslipidemia, and coronary heart disease
Timeline
Screening 3 weeks
Treatment Varies
Follow Up before and after a 6-weeks supplementation
Awards & highlights

FAS Trial Summary

This trial looks at the effects of a type of fish oil on metabolic risk factors, and whether individual genetic variation affects those results.

Who is the study for?
This trial is for healthy adults aged 18-50 with a BMI of 25-40kg/m2 and normal triglyceride levels. Participants should not smoke, drink alcohol regularly, or have thyroid/metabolic disorders like diabetes or severe dyslipidemia. Pregnant/nursing women and those on certain medications are excluded.Check my eligibility
What is being tested?
The study is testing the effects of n-3 PUFA (Omega-3 fatty acid) supplements on metabolic risk factors related to cardiovascular disease, considering genetic variations that might affect how individuals respond to these fats.See study design
What are the potential side effects?
While specific side effects aren't listed, Omega-3 supplements may sometimes cause mild digestive issues, fishy aftertaste, and increased bleeding tendency in some people.

FAS Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am between 18 and 50 years old and healthy.
Select...
I do not have diabetes, high blood pressure, severe cholesterol issues, or heart disease.

FAS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~before and after a 6-weeks supplementation
This trial's timeline: 3 weeks for screening, Varies for treatment, and before and after a 6-weeks supplementation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in blood lipids (Total cholesterol, HDL-Cholesterol, Triglycerides)
Secondary outcome measures
Change in anthropometric measures (waist and hip girth)
Change in blood pressure
Change in gene expression levels
+1 more

FAS Trial Design

1Treatment groups
Experimental Treatment
Group I: capsules omega-3Experimental Treatment1 Intervention
Omega-3 supplementation (3g EPA+DHA/d)

Find a Location

Who is running the clinical trial?

Laval UniversityLead Sponsor
416 Previous Clinical Trials
172,076 Total Patients Enrolled
Marie-Claude Vohl, Ph.D.Principal InvestigatorInstitute of Nutraceutical and Functional Foods (INAF), Laval University

Media Library

n-3 PUFA Supplementation (Omega-3 Fatty Acids) Clinical Trial Eligibility Overview. Trial Name: NCT01343342 — N/A
Cardiovascular Disease Research Study Groups: capsules omega-3
Cardiovascular Disease Clinical Trial 2023: n-3 PUFA Supplementation Highlights & Side Effects. Trial Name: NCT01343342 — N/A
n-3 PUFA Supplementation (Omega-3 Fatty Acids) 2023 Treatment Timeline for Medical Study. Trial Name: NCT01343342 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are new participants being added to this experiment?

"According to clinicaltrials.gov, this investigation is not currently accepting participants despite having been posted on October 1st 2009 and last modified in September 6th 2022. Fortunately, 427 other investigations are actively recruiting patients right now."

Answered by AI

Is this clinical experiment open to those aged 65 or older?

"The age range for this medical trial is 18 to 50, as indicated by the participating requirements."

Answered by AI

What are the criteria for eligible enrolment in this clinical trial?

"To gain acceptance into this medical trial, prospective participants must have a cardiovascular illness and be between 18-50 years of age. 200 patients need to take part in the study overall."

Answered by AI
Recent research and studies
~13 spots leftby Mar 2025